Jyothy Labs Limited has formally informed the stock exchanges regarding its decision to pursue legal remedies against Henkel AG & Co. KGaA. This action follows discussions regarding the non-renewal of the license agreements for the Pril and Fa brands. The company has concluded, after evaluating its options, that it must assert its contractual rights concerning the exit and transition mechanisms stipulated in the existing License Agreements and Technology License Agreements dated May 31, 2011.

Paragraph 2: The dispute centers on the manufacturing, distribution, marketing, and sale rights of the Pril and Fa brands in India. Following recent communications from Henkel, Jyothy Labs has initiated formal steps to address the termination impact and transition protocols. The company has committed to keeping investors updated on any material developments regarding this legal process as they arise.

Paragraph 3: Jyothy Labs is a prominent player in the Indian FMCG sector, known for its diverse portfolio in fabric care, dishwashing, household insecticides, and personal care. In 2025, the company focused on driving volume-led growth through innovations like “Ujala Young & Fresh” and expanding its reach across modern trade and e-commerce channels. Despite facing inflationary pressures and muted consumption trends throughout 2025, the company has prioritized cost control and premiumization to maintain its market position.

Paragraph 4: For the quarter ended March 2025 (Q4 FY2025), Jyothy Labs reported consolidated revenue of ₹682.44 Cr, reflecting a 1.41% increase compared to the corresponding quarter of the previous year. Net profit stood at ₹76.30 Cr, marking a decline of 2.38% over the same period. On a sequential basis, revenue fell by 4.99% and net profit dropped by 12.71% compared to the previous quarter. Nalanda Capital Pte Ltd and Nalanda India Equity Fund Limited remain significant institutional investors in the company, holding a combined stake of 5.72% as of December 2025.